Med24
peptide-development 10. 11. 2026 • 2 min read • Diabetes, obesity & metabolism

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits...

Knowledge and self-reported practice of laboratory biosafety among medical laboratory professionals in selected public and private hospitals in Mogadishu, Somalia: a cross-sectional study

A study compared semaglutide and tirzepatide in individuals with overweight or obesity and atherosclerotic cardiovascular disease (ASCVD) without diabetes. The study utilized national claims data to emulate a trial.

Study Design and Patient Population

Inclusion criteria specified a BMI of 27 or greater with an ASCVD diagnosis, continuous insurance coverage, and no prior GLP-1 receptor agonist or obesity medication use. The primary outcome was a composite of major adverse cardiovascular events (MACE), including myocardial infarction, stroke, heart failure hospitalization, unstable angina, coronary revascularization, and mortality.

Key Clinical Findings

Hazard ratios were estimated using Cox models with inverse probability weighting. The analysis found a non-significant difference in the risk of revised 5-point MACE between the two treatments. Secondary outcomes, including revised 3-point MACE and individual endpoints, also showed no significant difference.

Sponsored content

Sensitivity analyses were performed, highlighting the impact of early events, off-label use, analytic approach, and outcome definition on the results. The study indicated that among adults with overweight or obesity and ASCVD without diabetes, there was no significant difference in cardiovascular risk between semaglutide and tirzepatide.

Original Scientific Source
Diabetes, obesity & metabolism
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
peptide-development

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight...

1. 12. 2026 Read article →
The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome
peptide-development

The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome

Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and...

23. 10. 2026 Read article →
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
peptide-development

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence...

16. 10. 2026 Read article →
Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity
peptide-development

Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity

Aims Glucagon-like peptide-1 (GLP-1) receptor agonist-based medicines are highly effective treatments for overweight and obesity, but population-scale real-world evidence remains limited, particularly in self-funded settings where treatment choice may be influenced by relative price. We aimed to characterise provider...

14. 10. 2026 Read article →
Advertisement